Here are 100 books that The Right Price fans have personally recommended if you like
The Right Price.
Book DNA is a community of 12,000+ authors and super readers sharing their favorite books with the world.
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
This account of the early years of Vertex Pharmaceuticals, from its inception as a scrappy start-up to its early work in HIV, is a must-read classic for anyone interested in how science turns into new drugs. Barry Werth’s journalistic play-by-play is a cinematic, true-to-life picture of the strategic decisions, real-world challenges, and larger-than-life personalities that underlie modern drug development. His riveting follow-up, The Antidote, continues the saga by taking readers through Vertex’s pathbreaking work to transform the care of patients with hepatitis C and cystic fibrosis.
It is April 1st, 2038. Day 60 of China's blockade of the rebel island of Taiwan.
The US government has agreed to provide Taiwan with a weapons system so advanced that it can disrupt the balance of power in the region. But what pilot would be crazy enough to run…
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
Since Nixon’s "War on Cancer," oncology treatment has seen some great advances, but also the approval of scores of over-priced drugs that do little to improve patients’ quality or quantity of life. Oncologist Vinay Prasad has written a broad, accessible overview of the flaws of modern cancer drug development that spans clinical trial design, conflicts of interest, regulatory policy, and more. His unabashedly anti-pharma stance gets preachy in places, but most of the challenges he identifies are spot-on and provide a thought-provoking roadmap for the future.
How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective.
Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel-but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology…
I am the former president of Pfizer Global Research, where I led research groups around the globe in finding new medicines to treat cancer, addiction, AIDS, immunological diseases, and pain. After retiring from Pfizer, I have been closely involved with biotech companies that also are seeking breakthrough drugs. This industry is a crucial part of the healthcare ecosystem, as evidenced by the remarkable response and, ultimately, the crushing of the COVID-19 pandemic. Yet, it is not just underappreciated but is treated with scorn by many. This booklist provides sources from which the reader can gain a full understanding of the value of the biopharmaceutical industry, the challenges it faces, and its importance to the world’s health.
Legislators and healthcare insurers are seeking ways to slash healthcare costs, often focusing on cutting the costs of medicines through schemes like price controls. Yet, drugs make up only about 13 percent of the money paid on healthcare. This book does a great job of explaining what is behind the pricing of new drugs but, more importantly, shows that all life-saving drugs eventually become low-cost generics – truly a Great American Drug Deal.
This book scrutinizes all players in the healthcare industry and offers new ideas for cost-saving measures, such as closing loopholes, dealing with bad actors, and educating consumers. If you want to understand how best to balance innovation and affordability, this book is a must-read.
Developing life-changing drugs is risky and expensive—but that’s not what makes them unaffordable.Drug pricing is a staple of every news cycle and political debate. And while we’ve struggled for decades to agree on solutions that serve all patients without jeopardizing the invention of new medicines, many Americans suffer because they can’t afford the drugs they need.Do we really have to choose between affordability and innovation?In The Great American Drug Deal, scientist and industry expert Peter Kolchinsky answers this question with a decisive No. The pharmaceutical industry’s commitment to creating new lifesaving drugs destined to become inexpensive generics can be balanced…
A Duke with rigid opinions, a Lady whose beliefs conflict with his, a long disputed parcel of land, a conniving neighbour, a desperate collaboration, a failure of trust, a love found despite it all.
Alexander Cavendish, Duke of Ravensworth, returned from war to find that his father and brother had…
As a historian of science and medicine, I’m fascinated by the many ways that drugs—from tea to opiates, Prozac to psychedelics—have shaped our world. After all, there are few adults on the planet today who don’t regularly consume substances that have been classified as a drug at one time or another (I’m looking at you, coffee and tea!). The books I’ve selected here have deeply influenced my own thinking on the history of drugs over the past decade, from my first book, The Age of Intoxication, to my new book on the history of psychedelic science.
I admire the way that Jungle Laboratories weaves together the story of something globally famous—the birth control pill—with an untold history of a specific time and place in rural Mexico.
In this superbly researched book, Harvard History of Science professor Gabriela Soto Laveaga reveals how the yam fields of Veracruz became improbable sites of pharmaceutical innovation in the years during and after World War II. This book is a model of transnational history at its finest and a strikingly original take on the history of pharmacy, gender, labor, and global science.
In the 1940s chemists discovered that barbasco, a wild yam indigenous to Mexico, could be used to mass-produce synthetic steroid hormones. Barbasco spurred the development of new drugs, including cortisone and the first viable oral contraceptives, and positioned Mexico as a major player in the global pharmaceutical industry. Yet few people today are aware of Mexico's role in achieving these advances in modern medicine. In Jungle Laboratories, Gabriela Soto Laveaga reconstructs the story of how rural yam pickers, international pharmaceutical companies, and the Mexican state collaborated and collided over the barbasco. By so doing, she sheds important light on a…
As a cancer doctor, I have spent two decades dedicated to understanding the causes and therapy of cancer, how my patients experience their diagnosis and treatment, and how meaningful improvements in their experience should be reflected in the criteria we use to approve cancer drugs approval in the U.S., to improve their lives. In over 100 essays published in outlets like The New York Times and The Washington Post and in two books, I sing the stories of my patients as I learn from their undaunted spirits and their utter humanity, as I try to figure out how to be a better doctor, and a better person.
There’s a seedy side to the pharmaceutical industry that started well before the creation of the FDA, and continues through the modern era, fueling the epidemic of opioid drug dependency.
In Pharma, Posner’s comprehensive reporting introduces us to brilliant scientists, incorruptible government regulators, and brave whistleblowers facing off against company executives often blinded by greed.
We learn how the Sacklers built a culture of pain relief on the shoulders of oxycontin – one that ultimately led to the lowest survival rates for Americans in a century.
Award-winning journalist and New York Times bestselling author Gerald Posner traces the heroes and villains of the trillion-dollar-a-year pharmaceutical industry and uncovers how those once entrusted with improving life have often betrayed that ideal to corruption and reckless profiteering-with deadly consequences.
Pharmaceutical breakthroughs such as anti biotics and vaccines rank among some of the greatest advancements in human history. Yet exorbitant prices for life-saving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on pre scription opioids have caused many to lose faith in drug companies. Now, Americans are demanding a national reckoning…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
I found, as a history buff, The Struggle for Drug Reform to be an eye-opener about how America’s exceptionally high drug prices among other deficits in health care quality and coverage resulted from the past exercise of power by the pharmaceutical industry, the lynchpin of America’s “medico-industrial complex.”
I was impressed by historian Tobbell’s meticulously researched account of the industry’s strategic alliances with self-interested medical scientists, not just conservative political forces, and its use of anti-communist propaganda to fight off the threat of drug pricing regulations.
I personally found important her discussions of how the industry allied with the American Medical Association against universal health care, against FDA demands for evidence about drug efficacy and safety before allowing drugs on the market, and against the threat to its profits from generic drugs.
Since the 1950s, the American pharmaceutical industry has been heavily criticized for its profit levels, the high cost of prescription drugs, drug safety problems, and more, yet it has, together with the medical profession, staunchly and successfully opposed regulation. "Pills, Power, and Policy" offers a lucid history of how the American drug industry and key sectors of the medical profession came to be allies against pharmaceutical reform. It details the political strategies they have used to influence public opinion, shape legislative reform, and define the regulatory environment of prescription drugs. Untangling the complex relationships between drug companies, physicians, and academic…
The Duke's Christmas Redemption
by
Arietta Richmond,
A Duke who has rejected love, a Lady who dreams of a love match, an arranged marriage, a house full of secrets, a most unneighborly neighbor, a plot to destroy reputations, an unexpected love that redeems it all.
Lady Charlotte Wyndham, given in an arranged marriage to a man she…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
If you think that medical journals published by respected medical societies are full of good science, think again.
For me, Abramson’s Sickeningnailed the case for a conclusion that the net effect of the many hundreds of medical journals published here and around the world is to subtract from the sum of human medical knowledge.
Abramson, as an expert witness in criminal and civil cases against drug companies, draws in part on subpoenaed documents to expose how medical science, as part of the entire medical-industrial complex, is corrupted from start to finish by the drug industry’s funding of most clinical trials, their control over the data analysis, and even their ghost-writing of articles submitted to journals.
New and disturbing was the withholding of clinical trials’ raw data from journals’ peer reviewers. Instead, they get biased summaries bearing drug manufacturers’ fingerprints.
The inside story of how Big Pharma’s relentless pursuit of ever-higher profits corrupts medical knowledge—misleading doctors, misdirecting American health care, and harming our health.
The United States spends an excess $1.5 trillion annually on health care compared to other wealthy countries—yet the amount of time that Americans live in good health ranks a lowly 68th in the world. At the heart of the problem is Big Pharma, which funds most clinical trials and therefore controls the research agenda, withholds the real data from those trials as corporate secrets, and shapes most of the information relied upon by health care professionals.…
As a published author, Debra’s passion for fast-paced, unputdownable novels is unquenchable. She can be ruthless in her criticism, applying the rule, “three strikes and you’re out!” A firm believer that life is too short to read mediocre books, if she isn’t grabbed by chapter 3, she puts the book down and moves on. She wants a book to make her life better, she wants to feel excitement at picking it back up again, and burying herself in the characters and moods, twists and turns, of a great story. Her writing reflects this same trait, if her words won’t keep the reader totally engrossed, then she won’t write them.
One of my all-time favourites I’ve read this book 3 times now and, after this review, I’m sure I’ll be tempted to indulge myself for a fourth time. Follett is the master of knife-edge thrillers, if you’ve never read him, start now. Full of treachery and violence, twists and revelations. It’s a scary, but utterly brilliant read.
"Everyone likes a page-turner, and Follett is the best." -The Philadelphia Inquirer
"A hell of a storyteller" (Entertainment Weekly), #1 New York Times bestselling author Ken Follett reinvents the thriller with each new novel. But nothing matches the intricate knife-edge drama of Whiteout. . . .
A missing canister of a deadly virus. A lab technician bleeding from the eyes. Toni Gallo, the security director of a Scottish medical research firm, knows she has problems, but she has no idea of the nightmare to come.
As a Christmas Eve blizzard whips out of the north, several people, Toni among them,…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
I find Angell’sThe Truth About the Drug Companies extremely valuable for teaching students about how the pharmaceutical industry translates high profits into power resources to protect and increase those profits over time.
The former New England Journal of Medicine editor exposed how drug companies enlist politicians, the FDA, and medical academia for their cause. And armies of lawyers to extend monopoly marketing rights for years.
It was my first introduction to how they spend more on marketing than research, much of that on “copy-cat” drugs of dubious superiority to ones with expired patents.
As a tax (and high drug price) payer, I was disturbed to learn how they use government funds for basic research and then rig and spin their reporting of clinical studies to inflate their products’ therapeutic value and underplay their risks.
During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes…
This book follows the journey of a writer in search of wisdom as he narrates encounters with 12 distinguished American men over 80, including Paul Volcker, the former head of the Federal Reserve, and Denton Cooley, the world’s most famous heart surgeon.
In these and other intimate conversations, the book…
As a physician, medicine is my job. But along the way, I wondered how medicine got to where it is now–like really wondered. I wondered to the point that I was reading the original treatises written by 18th-century physicians. I started publishing research on medical history and giving presentations at medical conferences. I’d like to think this helps me be a better doctor by broadening my perspective on the healthcare industry. But at the very least, I’ve found these books enjoyable and compelling. I hope you enjoy them, too!
This remarkable story illustrates that if something in healthcare sounds too good to be true, it probably is. I had to stop listening to it before going to sleep because the compelling narrative was keeping me up at night.
The author seamlessly combined this compelling narrative with exceptional research behind the Food and Drug Administration, the heroine who prevented thalidomide approval in the United States, and the catastrophic effects of a pharmaceutical company using loopholes.
Longlisted for the Andrew 2024 Carnegie Medal for Non-Fiction
The shocking, never-before-told story of America's thalidomide victims
In Germany on Christmas Day 1956 a baby girl was born without ears. She was the first victim of the notorious thalidomide epidemic. There would be over 10,000 more across 46 countries.
For years the world believed the United States had avoided the catastrophe. After Frances Kelsey at the Food and Drug Administration became suspicious of the dangers of thalidomide in 1960, she led a successful fight to block its commercial approval.
But now, having probed government and corporate archives and interviewed hundreds…
